These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19398376)

  • 21. Complications after cardiac transplantation. The role of immunosuppression.
    Vargo RL; Whitman GR
    Crit Care Nurs Clin North Am; 1989 Dec; 1(4):741-52. PubMed ID: 2697223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intestinal transplantation: evolution in immunosuppression protocols.
    Pirenne J; Kawai M
    Curr Opin Organ Transplant; 2009 Jun; 14(3):250-5. PubMed ID: 19373085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can immune monitoring help to minimize immunosuppression in kidney transplantation?
    Ashton-Chess J; Giral M; Soulillou JP; Brouard S
    Transpl Int; 2009 Jan; 22(1):110-9. PubMed ID: 18764832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biologic monitoring of the efficacy of immunosuppression in liver transplant patients.
    Farges O; Buffello D; Swercz B; deGroote D; Bismuth H
    Transplant Proc; 1995 Aug; 27(4):2516-8. PubMed ID: 7652911
    [No Abstract]   [Full Text] [Related]  

  • 25. Immunosuppressive drug-free operational immune tolerance in human kidney transplant recipients: Part I. Blood gene expression statistical analysis.
    Braud C; Baeten D; Giral M; Pallier A; Ashton-Chess J; Braudeau C; Chevalier C; Lebars A; Léger J; Moreau A; Pechkova E; Nicolini C; Soulillou JP; Brouard S
    J Cell Biochem; 2008 Apr; 103(6):1681-92. PubMed ID: 17910029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunologic basis of allograft rejection and immunosuppressive agents in intestinal transplantation.
    Vianna R
    Minerva Pediatr; 2009 Jun; 61(3):293-303. PubMed ID: 19461573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kaposi's sarcoma and mTOR: a crossroad between viral infection neoangiogenesis and immunosuppression.
    Stallone G; Infante B; Grandaliano G; Schena FP; Gesualdo L
    Transpl Int; 2008 Sep; 21(9):825-32. PubMed ID: 18498314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microarrays: monitoring for transplant tolerance and mechanistic insights.
    Zarkhin V; Sarwal MM
    Clin Lab Med; 2008 Sep; 28(3):385-410, vi. PubMed ID: 19028259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stimulation index for PCNA mRNA in peripheral blood as immune function monitoring after renal transplantation.
    Niwa M; Miwa Y; Kuzuya T; Iwasaki K; Haneda M; Ueki T; Katayama A; Hiramitsu T; Goto N; Nagasaka T; Watarai Y; Uchida K; Nakao A; Kobayashi T
    Transplantation; 2009 May; 87(9):1411-4. PubMed ID: 19424044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer development in renal allograft recipients treated with conventional and cyclosporine immunosuppression.
    Gruber SA; Skjei KL; Sothern RB; Robison L; Tzardis P; Moss A; Gillingham K; Canafax DM; Matas AJ; Dunn DL
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1104-5. PubMed ID: 1989160
    [No Abstract]   [Full Text] [Related]  

  • 31. Use of an immune function assay to monitor immunosuppression.
    Grimm P
    Pediatr Transplant; 2006 Aug; 10(5):533-5. PubMed ID: 16856988
    [No Abstract]   [Full Text] [Related]  

  • 32. Can we use biomarkers and functional assays to implement personalized therapies in transplantation?
    Sawitzki B; Pascher A; Babel N; Reinke P; Volk HD
    Transplantation; 2009 Jun; 87(11):1595-601. PubMed ID: 19502949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacodynamic monitoring of the immunosuppressive therapy in patients after heart transplantation: whole blood flow cytometric analysis of lymphocyte function.
    Barten MJ; Rahmel A; Boldt A; Dhein S; Bittner HB; Tarnok A; Mohr FW; Gummert JF
    Comput Biol Med; 2007 Oct; 37(10):1367-73. PubMed ID: 17182025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A model for nurse-led skin cancer surveillance following renal transplantation.
    Reece SM; Harden PN; Smith AG; Ramsay HM
    Nephrol Nurs J; 2002 Jun; 29(3):257-9, 267. PubMed ID: 12164075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal transplant: long-term effects of immunosuppression.
    Hasselder A
    Prof Nurse; 1999 Aug; 14(11):771-6. PubMed ID: 10481707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Post-transplantation malignant tumors and the challenges of immunosuppressive therapy in transplanted patients developing lymphoma. Mycophenolic acid as a possibility].
    Végso G
    Magy Onkol; 2009 Jun; 53(2):149-56. PubMed ID: 19581181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunosuppression and skin cancer.
    Penn I
    Clin Plast Surg; 1980 Jul; 7(3):361-8. PubMed ID: 7002432
    [No Abstract]   [Full Text] [Related]  

  • 38. Immunosuppression and monitoring of rejection in hand transplantation.
    Schneeberger S; Khalifian S; Brandacher G
    Tech Hand Up Extrem Surg; 2013 Dec; 17(4):208-14. PubMed ID: 24275762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using biomarkers of tolerance and rejection to identify high- and low-risk patients following kidney transplantation.
    Ashton-Chess J; Giral M; Soulillou JP; Brouard S
    Transplantation; 2009 May; 87(9 Suppl):S95-9. PubMed ID: 19424020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Patients' knowledge of the risk of skin cancer following kidney transplantation].
    Cramer E; Rasmussen K; Jemec GB
    Ugeskr Laeger; 2009 Nov; 171(46):3341-5. PubMed ID: 19925738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.